Boundless Bio
$2.56
1
+$0.05+1.99% Friday 20:00
-$0.00-0.05%Friday 23:53After hours
Statistics
Day High
2.55
Day Low
2.54
52W High
2.6
52W Low
1.01
Volume
1,275
Avg. Volume
-
Mkt Cap
57.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
17AugExpected
Expected EPS
-0.6
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-130.73MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow BOLD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.41B
Editas Medicine
EDIT
Mkt Cap437.37M
Intellia Therapeutics
NTLA
Mkt Cap2.33B
Beam Therapeutics
BEAM
Mkt Cap3.58B
Sangamo Therapeutics
SGMO
Mkt Cap20.71M
Allogene Therapeutics
ALLO
Mkt Cap735.18M
Biomarin Pharmaceutical
BMRN
Mkt Cap11.4B
Fate Therapeutics
FATE
Mkt Cap243.61M
Adaptive Biotechnologies
ADPT
Mkt Cap3.35B
About
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Show more...
CEO
Mr. Zachary D. Hornby
Employees
64
Country
United States
ISIN
US10170A1007
Listings
0 Comments
Share your thoughts
FAQ
What is Boundless Bio stock price today?▼
The current price of BOLD is $2.56 USD — it has increased by +1.99% in the past 24 hours. Watch Boundless Bio stock price performance more closely on the chart.
What is Boundless Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Boundless Bio stocks are traded under the ticker BOLD.
Is Boundless Bio stock price growing?▼
BOLD stock has risen by +82.86% compared to the previous week, the month change is a +76.55% rise, over the last year Boundless Bio has showed a +153.47% increase.
What is Boundless Bio market cap?▼
Today Boundless Bio has the market capitalization of 57.31M
When is the next Boundless Bio earnings date?▼
Boundless Bio is going to release the next earnings report on August 17, 2026.
What were Boundless Bio earnings last quarter?▼
BOLD earnings for the last quarter are -0.6 USD per share, whereas the estimation was -0.58 USD resulting in a -4.05% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Boundless Bio revenue for the last year?▼
Boundless Bio revenue for the last year amounts to 0 USD.
What is Boundless Bio net income for the last year?▼
BOLD net income for the last year is -130.73M USD.
How many employees does Boundless Bio have?▼
As of June 29, 2026, the company has 64 employees.
In which sector is Boundless Bio located?▼
Boundless Bio operates in the Health & Wellness sector.
When did Boundless Bio complete a stock split?▼
Boundless Bio has not had any recent stock splits.
Where is Boundless Bio headquartered?▼
Boundless Bio is headquartered in San Diego, United States.